Venture capital fund
Brisbane, QLD
Every published round Blue Sky Alternative Investments took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Blue Sky Alternative Investments has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Blue Sky Alternative Investments, as distinct from the investments it has made.
Companies Blue Sky Alternative Investments has backed that another company then bought. An exit for the holding, not a deal Blue Sky Alternative Investments did.
Stories naming Blue Sky Alternative Investments. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Venture firm Touch Ventures debuted on the ASX, raising $100 million in its IPO and closing sharply higher; Afterpay backed it, and the firm recently put $1 million into Refundid's seed round.
The South Australian Venture Capital Fund, idle since Blue Sky's collapse, has appointed Artesian as manager with David Rohrsheim leading locally; past fund investments in Myriota and Fivecast are recalled.
Hatchtech announced FDA sign-off on its DeOvo Phase 3 trials and two extra patents; its profile names GBS Venture Partners among the company's investors.
Melbourne drug developer Hatchtech raised A$12.6 million, with OneVentures Innovation Fund leading, to advance its head lice treatment toward Phase III trials; board changes brought in Richard Treagus and Hugh Alsop.